Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690401 · ClinicalTrials.gov registry record
Body Composition Post Cancer Treatment
A clinical trial of Cancer, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT03690401 is a study of Cancer that has completed, run by Prisma Health-Upstate. The registered enrollment target is 52 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03690401, a study of Cancer, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess how bone density and body composition changes after a cancer patient completes treatment and through 12-weeks post-treatment. Patients who enroll in the 12-week exercise program, Moving On, and those that do not elect to participate in the Moving On program will both be tracked, with assessments including SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments.
Conditions Studied
Interventions
- DEVICE SOZO Device
- DEVICE DEXA Scan
Study Locations (1)
South Carolina
- Prisma Health Cancer Institute Center for Integrative Oncology and Survivorship - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690401
The ClinicalTrials.gov registry entry for NCT03690401 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOZO Device is the first listed.
NCT03690401 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT03690401 about?
NCT03690401 is a clinical study titled "Body Composition Post Cancer Treatment". The purpose of this study is to assess how bone density and body composition changes after a cancer patient completes treatment and through 12-weeks post-treatment. Patients who enroll in the 12-week exercise program, Moving On, and those that do not elect to participate in the Moving On program wil...
What is the current status of trial NCT03690401?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2018-10-01. Estimated completion is 2023-11-15.
What conditions does trial NCT03690401 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03690401?
The interventions under investigation include: SOZO Device (DEVICE), DEXA Scan (DEVICE).
Who is sponsoring clinical trial NCT03690401?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03690401 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.